difluprednate and Pain

To assess the efficacy and safety of difluprednate ophthalmic emulsion 0.05% (Durezol) 2 or 4 times a day compared with those of a placebo in the treatment of inflammation and pain associated with ocular surgery.. Twenty-six clinics in the United States.. One day after unilateral ocular surgery, patients who had an anterior chamber cell grade of 2 or higher (>10 cells) were treated with 1 drop of difluprednate 2 times or 4 times a day or with a placebo (vehicle) 2 times or 4 times a day in the study eye for 14 days. This was followed by a 14-day tapering period and a 7-day safety evaluation. Outcome measures included cleared anterior chamber inflammation (grade 0, or=10 mm Hg and >or=21 mm Hg from baseline, respectively) versus 1% in the placebo group.. Difluprednate given 2 or 4 times a day cleared postoperative inflammation and reduced pain rapidly and effectively. There were no serious ocular adverse events. Fewer adverse events were reported in the difluprednate-treated groups than in the placebo group.

Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Cell Count; Double-Blind Method; Emulsions; Female; Fluprednisolone; Glucocorticoids; Humans; Inflammation; Male; Middle Aged; Ophthalmic Solutions; Ophthalmologic Surgical Procedures; Pain; Postoperative Complications; Uveitis, Anterior

Topics: Administration, Cutaneous; Aged; Animals; Bees; Female; Fluprednisolone; Glucocorticoids; Humans; Insect Bites and Stings; Knee; Pain; Seasons